Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Dendritic Cell Immunotherapy in Breast Cancer
NCT03113019Phase 1Unknown
- Sponsor
- Research Institute of Fundamental and Clinical Immunology
- Start
- Feb 2014
- Primary completion
- Feb 2017
01
Overview
Phase 1, open-label, single-arm trial in breast cancer, sponsored by Research Institute of Fundamental and Clinical Immunology. Primary endpoint: Cytotoxicity at 6 months. Status: unknown.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03113019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03113019.